Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

Clinical trial NCT07778212 · RECRUITING

Trial details

NCT number: NCT07778212
Sponsor: The First Affiliated Hospital of Xiamen University
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

DLBCL - Diffuse Large B Cell Lymphoma Intermediate-High Risk First-Line

Start date: 2026-08-30
Primary completion: 2027-09-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.